FDA Approves Novartis’s Cosentyx for Polymyalgia Rheumatica, First Biologic of Its Kind for the Condition
The US Food and Drug Administration has approved Novartis’s Cosentyx for adults with polymyalgia rheumatica, giving patients over 50 a first alternative to long-term steroid treatment.
